Despite ongoing economic uncertainty, the UK’s pharmaceutical and biotechnology sector is delivering encouraging news. From major investment announcements to cutting-edge collaborations and breakthrough therapies, the industry is demonstrating why it remains one of the world’s leading life sciences hubs.

The global obesity treatment market is rapidly evolving from a neglected therapeutic area into one of the most valuable segments in healthcare. Driven by breakthrough weight-loss medicines and a growing patient population, analysts predict it could rival oncology and immunology in market value within the next decade.